RANI Rani Therapeutics Holdings Forecast, Technical & Fundamental Analysis
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections... Show more
RANI is expected to report earnings to rise 22.75% to -4 cents per share on August 06
Q2'26
Est.
$-0.05
Q1'26
Beat
by $0.01
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.05
Q2'25
Beat
by $0.11
The last earnings report on May 15 showed earnings per share of -3 cents, beating the estimate of -5 cents. With 297.15K shares outstanding, the current market capitalization sits at 87.00M.
A.I.dvisor indicates that over the last year, RANI has been loosely correlated with ARTV. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if RANI jumps, then ARTV could also see price increases.
RANI in downward trend: price dove below 50-day moving average on July 31, 2026
RANI moved below its 50-day moving average on July 31, 2026 date and that indicates a change from an upward trend to a downward trend. In of 48 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RANI moved out of overbought territory on July 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 44 cases where RANI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RANI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RANI broke above its upper Bollinger Band on July 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RANI entered a downward trend on July 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 22, 2026. You may want to consider a long position or call options on RANI as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RANI just turned positive on July 17, 2026. Looking at past instances where RANI's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for RANI crossed bullishly above the 50-day moving average on July 31, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RANI advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.063) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (25.126) is also within normal values, averaging (420.906).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
